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Abstract: Angiogenesis is considered responsible for the growth of primary tumours and of their
metastases. With the present study, the effects of three ruthenium compounds, potassiumchlorido
(ethylendiamminotetraacetate)rutenate(III) (RuEDTA), sodium (bis-indazole)tetrachloro-ruthenate
(III), Na[trans-RuCl4Ind2] (KP1339) and trans-imidazoledimethylsulphoxidetetrachloro-ruthenate
(NAMI-A), are studied in vitro in models mimicking the angiogenic process. The ruthenium
compounds reduced the production and the release of nitrosyls from either healthy macrophages
and immortalized EA.hy926 endothelial cells. The effects of NAMI-A are qualitatively similar
and sometimes quantitatively superior to those of RuEDTA and KP1339. NAMI-A reduces the
production and release of nitric oxide (NO) by the EA.hy926 endothelial cells and correspondingly
inhibits their invasive ability; it also strongly inhibits the angiogenesis in matrigel sponges implanted
subcutaneously in healthy mice. Taken together, these data support the anti-angiogenic activity of the
tested ruthenium compounds and they contribute to explain the selective activity of NAMI-A against
solid tumour metastases, the tumour compartment on which angiogenesis is strongly involved. This
anti-angiogenic effect may also contribute to the inhibition of the release of metastatic cells from the
primary tumour. Investigations on the anti-angiogenic effects of NAMI-A at this level will increase
knowledge of its pharmacological properties and it will give a further impulse to the development of
this class of innovative metal-based drugs.
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1. Introduction
The role of the angiogenic processes for cancer growth and dissemination has been long
demonstrated and angiogenesis identified as a target for the pharmacological control of tumour
malignancy [1–4]. A significant example of anti-angiogenic drug is Avastin (bevacizumab),
a monoclonal antibody that changed the treatment paradigm of tumours such as colorectal cancer [5].
The pharmacological control of tumour angiogenesis, besides the use of specific monoclonal antibodies
directed to vascular endothelial growth factor (VEGF) (see the above reported Avastin), can be
controlled with tyrosine kinase inhibitors (TKIs, for example Sunitinib [6]) that block the signalling
pathway that activates the angiogenic processes, and/or by the use of chemicals that interrupt
the signalling between cells (for example Lenalidomide, the levo enantiomer of the old drug
Thalidomide [7]). Independently of the type of drug being used, and of its mechanism of action,
the main pharmacological effect expected is the arrest of the formation of new vessels, induced by the
tumour, and correspondingly the block to the growth of the tumour because of the inhibited arrival of
nutrients to the cells of the tumour mass.
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Ruthenium-based drugs have also shown the ability to control the phenomena related to
angiogenesis. In particular, imidazolium trans-imidazoledimethylsulphoxidetetrachloro-ruthenate
(NAMI-A) inhibits the angiogenic process mimicked in the chick embryo chorioallantoic membrane
(CAM) model [8] and in the pellets implanted in the rabbit cornea [9]. A more detailed study with
the endothelial cell line ECV304 has clarified how NAMI-A was able to inhibit the growth of these
cells through the inhibition of the receptor activated signal-extracellular regulated kinase (RAS-ERK)
pathway at concentrations compatible with those reached in vivo in the metastatic sites [10–12].
The mechanism by which NAMI-A can control tumour angiogenesis has not been elucidated yet and
support to this activity only comes from the observation that it is able to bind nitric oxide (NO), then
reducing the activity of this gaseous transmitter that cancer cells use to modulate the angiogenesis on
the endothelial cells [13–15].
The aim of the present study was therefore that of examining the pharmacological actions of
NAMI-A, compared to those of two other ruthenium-based compounds (KP1339 and RuEDTA),
in relation to their capacity to scavenge the nitric oxide. It is important to remember that the scavenging
activity of NO of these compounds has already been studied through fourier transform infrared
spectroscopy (FT-IR) and 1H-nuclear magnetic resonance (1H-NMR) spectroscopy techniques [9].
Here, the study will focus on the use of two in vitro cell models, the peritoneal murine macrophages
(a cell population present in the tumour masses and to which the capacity to produce and release large
quantities of NO is attributed [16]) and the human endothelial-like immortalised cell line EA.hy926 [17],
and on the use of rat aorta rings cultured in vitro. Matrigel™ pellets implanted subcutaneously in
mice will add further data from in vivo studies.
2. Results
2.1. Murine Peritoneal Macrophage Model
Effects on Nitric Oxide (NO) Production
Upon treatment with lipopolysaccharide (LPS), which is known to stimulate the inducible
form of nitric oxide synthase (NOS), murine peritoneal macrophages are strongly activated
to produce nitric oxide (NO) (Figure 1). The contemporary treatment with 2-phenyl-4,4,5,5-
tetramethylimidazoline-1-oxyl 3-oxide (PTIO) (used as the NO scavenger) significantly increased
the extracellular NO2´ concentration as detected by the Griess test. This effect is consequent to the
mechanism by which PTIO exerts its NO scavenging activity; PTIO oxidises the excess of NO released
in the extracellular medium, transforming it into NO2´, which is then detected by the Griess test as an
increase of NO2´ concentration (Figure 1). The treatment of murine peritoneal macrophages with 10´4
and 3 ˆ 10´4 M NAMI-A significantly reduced the release of NO in the extracellular medium, that had
been induced by the contemporary stimulation with LPS (Figure 2). The effect is comparable to that of
equal concentrations of Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), the well-known
inhibitor of NOS. The treatment with potassiumchlorido (ethylendiamminotetraacetate)rutenate(III)
(RuEDTA) is even more effective, showing a reduction of NO release of about 90% in comparison
to untreated controls. The ruthenium compounds maintained their ability to lower the NO release
also when the cells were treated before being activated with LPS (Figure 3). In this case, the reduction
of NO release was quantitatively less relevant than that measured in the contemporary treatment
reported in Figure 2, and it was similar for NAMI-A and RuEDTA (reduction of approximately 25%).
The pre-treatment with sodium (bis-indazole)tetrachloro-ruthenate(III), Na[trans-RuCl4Ind2] (KP1339)
was somewhat less effective.
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Figure 1. Nitric oxide (NO) release in the extracellular medium by macrophages. Murine peritoneal 
macrophages were treated for 24 h with 10 μg/mL lipopolysaccharide (LPS) and with 3 × 10−4 M 
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO), then NO release in the extracellular 
medium was measured by the Griess test. Data are the mean ± standard error medium (S.E.M.) of 
five samples per group. Unpaired t-test: *** p < 0.001 vs. no LPS no PTIO; °°° p < 0.001 vs. LPS. 
 
Figure 2. Effects of ruthenium compounds on the NO production by macrophages. Murine 
peritoneal macrophages were treated for 24 h with 10 μg/mL LPS and contemporary with 10−5,  
10−4, and 3 × 10−4 M of Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME), imidazolium 
trans-imidazoledimethylsulfoxidetetrachloro-ruthenate (NAMI-A), and potassiumchlorido 
(ethylendiamminotetraacetate)rutenate(III) (RuEDTA). NO release in the extracellular medium was 
measured by the Griess test. Data are expressed as per cent of variation vs. the controls and are the 
mean ± S.E.M. of five samples per group. ANOVA and Tukey–Kramer: * p < 0.05, *** p < 0.001 vs. Control. 
Figure 1. Nitric oxide (NO) release in the extracellular medium by macrophages. Murine peritoneal
macrophages were treated for 24 h with 10 µg/mL lipopolysaccharide (LPS) and with 3 ˆ 10´4 M
2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO), then NO release in the extracellular
medium was measured by the Griess test. Data are the mean ˘ standard error medium (S.E.M.) of five
samples per group. Unpaired t-test: *** p < 0.001 vs. no LPS no PTIO; ˝˝˝ p < 0.001 vs. LPS.
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Figure 3. Effects of the pre-treatment with the ruthenium compounds on the NO production by 
macrophages. Murine peritoneal macrophages were treated with 10−4 M NAMI-A, RuEDTA, and 
sodium (bis-indazole)tetrachloro-ruthenate(III), Na[trans-RuCl4Ind2] (KP1339), then washed and 
further treated for 24 h with 10 μg/mL LPS. NO release in the extracellular medium was measured by 
the Griess test. Data are expressed as per cent of variation vs. the controls and are the mean ± S.E.M. 
of five samples per group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control; °°° p < 0.001 vs. KP1339. 
2.2. EA.Hy926 Endothelial Cell Line Model 
2.2.1. Cytotoxicity Test 
Before examining the activity of the ruthenium compounds on the NO production of the 
EA.hy926 endothelial cell line, we studied their effects on the cell viability after cell treatment for  
48 or 72 h (Figure 4A,B, respectively). The same test was done with the NO scavenger PTIO, with the 
NOS inhibitor L-NAME, and with the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP), using 
the same experimental conditions. Among the ruthenium compounds tested, KP1339 was the most 
cytotoxic, with IC50 values in the 10−5 M range after either 48 or 72 h of cell exposure (Table 1). 
NAMI-A and RuEDTA showed a quite similar activity on the endothelial cell viability being able to 
significantly reduce it only after treatment at the highest concentration tested (10−3 M). The NOS 
inhibitor, L-NAME, was virtually devoid of any cytotoxicity up to the maximum concentration used, 
i.e., 10−3 M. SNAP and PTIO significantly affected cell viability after treatments at the two highest 
concentrations tested (10−4 and 10−3 M). 
Table 1. IC50 values of imidazolium trans-imidazoledimethylsulfoxidetetrachloro-ruthenate 
(NAMI-A), potassiumchlorido(ethylendiamminotetraacetate)rutenate(III) (RuEDTA), sodium 
(bis-indazole)tetrachloro-ruthenate(III), Na[trans-RuCl4Ind2] (KP1339), 2-phenyl-4,4,5,5- 
tetramethylimidazoline-1-oxyl 3-oxide (PTIO), S-nitroso-N-acetyl-DL-penicillamine (SNAP), and 
Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) in EA.hy926 cells. 
Compound 
IC50 [μM]
48 h 72 h
NAMI-A 960 (623–1481) 360 (150–885) 
RuEDTA >1000 880 (507–1534) 
KP1339 37 (20–68) 22 (12–38) 
PTIO 87 94 
SNAP 500 (85–2893) 220 (85–599) 
L-NAME >1000 >1000 
EA.hy926 cells were treated with NAMI-A, RuEDTA, KP1339, PTIO, SNAP, and L-NAME at 10−6–10−3 M 
for 48 or 72 h before measuring cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) test. Values in parentheses represent the 95% Confidence Intervals. 
Figure 3. Effects of the pre-treatment with the ruthenium compounds on the NO production by
macrophages. Murine peritoneal macrophages were treated with 10´4 M NAMI-A, RuEDTA, and
sodium (bis-indazole)tetrachloro-ruthenate(III), Na[trans-RuCl4Ind2] (KP1339), then washed and
further treated for 24 h with 10 µg/mL LPS. NO release in the extracellular medium was measured by
the Griess test. Data are expressed as per cent of variation vs. the controls and are the mean ˘ S.E.M. of
five samples per group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control; ˝˝˝ p < 0.001 vs. KP1339.
2.2. EA.Hy926 Endothelial Cell Line Model
2.2.1. Cytot xicity Test
Before examining the activity of the ruthenium compounds on the NO production of the EA.hy926
endothelial cell line, we studied their effects on the cell viability after cell treatment for 48 or 72 h
(Figure 4A,B, respectively). The same test was done with the NO scavenger PTIO, with the NOS
inhibit r L-NAME, and with the NO donor S-nitroso-N-acetyl-DL-penicillamine (SNAP), using the
same experimental conditions. Among the uthenium compounds tested, KP1339 w s the most
cytotoxic, with IC50 values in the 10´5 M r ng after either 48 or 72 h of cell exposure (Table 1).
NAMI-A and RuEDTA showed a quite similar activity on the endothelial cell viability being able to
significantly reduce it only after treatment at the highest concentration tested (10´3 M). The NOS
inhibitor, L-NAME, was virtually devoid of any cytotoxicity up to the maximum concentration used,
i.e., 10´3 M. SNAP and PTIO significantly affected cell viability after treatments at the two highest
concentrations tested (10´4 and 10´3 M).
Table 1. IC50 values of imidazolium trans-imidazoledimethylsulfoxidetetrachloro-ruthenate (NAMI-A),
potassiumchlorido(ethylendiamminotetraacetate)rutenate(III) (RuEDTA), sodium (bis-indazole)
tetrachloro-ruthenate(III), Na[trans-RuCl4Ind2] (KP1339), 2-phenyl-4,4,5,5-tetramethylimidazoline-
1-oxyl 3-oxide (PTIO), S-nitr so-N-acetyl-DL-penicillamine (SNAP), and Nω-nitro-L-arginine methyl
ester hydrochloride (L-NAME) in EA.hy926 cells.
Compound
IC50 [µM]
48 h 72 h
NAMI-A 960 (623–1481) 360 (150–885)
RuEDTA >1000 880 (507–1534)
KP1339 37 (20–68) 22 (12–38)
PTIO 87 94
SNAP 500 (85–2893) 220 (85–599)
L-NAME >1000 >1000
EA.hy926 cells were treated with NAMI-A, RuEDTA, KP1339, PTIO, SNAP, and L-NAME at 10´6–10´3 M for 48
or 72 h before measuring cell viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
test. Values in parentheses represent the 95% Confidence Intervals.
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Figure 4. EA.hy926 cell viability after treatment with NAMI-A, RuEDTA, KP1339, PTIO, SNAP, and 
L-NAME. EA.hy926 cells were treated with compounds 10−6–10−3 M for: 48 h (A); or 72 h (B). Cell viability 
was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test. 
2.2.2. Cell Invasion Test 
NAMI-A significantly reduced, in a concentration-dependent manner, the invasive ability of 
the EA.hy926 endothelial cells (Figure 5). RuEDTA was also effective, although to a lesser extent 
(−17% at 3 × 10−4 M compared to −45% of NAMI-A at equimolar concentrations), and its activity was 
similar to that of the NOS inhibitor L-NAME. The NO donor SNAP significantly decreased the 
invasion of the endothelial cells, although this effect seemed mostly related to its cytotoxicity, 
consequent to the consistent release of NO that it induced at the highest concentration tested. 
 
Figure 5. Effects of NAMI-A, RuEDTA, L-NAME, and SNAP on the invasive ability of EA.hy926 
cells. EA.hy926 cells were treated with compounds at 10−5, 10−4, and 3 × 10−4 M for 24 h before seeding 
them on Transwell® filters. Cell invasion was detected after further 24 h at 37 °C 5% CO2. Data are 
expressed as per cent of variation vs. the controls and are the mean ± S.E.M. of three samples per 
group. ANOVA and Tukey–Kramer: ** p < 0.01, *** p < 0.001 vs. Control. 
Figure 4. EA.hy926 cell viability after treatment with NAMI-A, RuEDTA, KP1339, PTIO, SNAP,
and L-NAME. EA.hy926 cells were treated with compou ds 10´6–10´3 M for: 48 h (A); or 72 h (B).
Cell viability was measured with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) test.
2.2.2. Cell Invasion Test
NAMI-A significantly reduced, in a concentration-depe dent manner, the invasive ability of the
EA.hy926 endothelial cells (Figure 5). RuEDTA was also effective, al hough to a lesser extent (´17% at
3 ˆ 10´4 M compared to ´45% of NAMI-A at equimolar concentrations), and its activity was similar
to that of the NOS inhibitor L-NAME. The NO donor SNAP significantly decreased the invasion of
the endothelial cells, although this effect seemed mostly related to its cytotoxicity, consequent to the
consistent release of NO that it induced at the highest concentration tested.
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cells. EA.hy926 cells were treated with compounds at 10−5, 10−4, and 3 × 10−4 M for 24 h before seeding 
them on Transwell® filters. Cell invasion was detected after further 24 h at 37 °C 5% CO2. Data are 
expressed as per cent of variation vs. the controls and are the mean ± S.E.M. of three samples per 
group. ANOVA and Tukey–Kramer: ** p < 0.01, *** p < 0.001 vs. Control. 
Figure 5. Effects of NAMI-A, RuEDTA, L-NAME, and SNAP on the invasive ability of EA.hy926 cells.
EA.hy926 cells were treated with compounds at 10´5, 10´4, and 3 ˆ 10´4 M for 24 h before seeding
them on Transwell® filters. Cell invasion was detected after further 24 h at 37 ˝C 5% CO2. Data are
expressed as per cent of variation vs. the controls and are the mean ˘ S.E.M. of three samples per
group. ANOVA and Tukey–Kramer: ** p < 0.01, *** p < 0.001 vs. Control.
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2.2.3. NO Production and Release
The basal release of NO by EA.hy926 cells is rather low; therefore an experimental condition
of high level of exogenous NO was generated using the NO donor compound SNAP. To maximally
limit the drawbacks of the production of NO at non-physiological levels, the time exposure of cells to
SNAP was secured at 2 h. With these experimental conditions, SNAP significantly increased the NO
levels starting from 10´5 and 10´4 M, respectively, in the extracellular medium (Figure 6A) and inside
the treated cells (Figure 6B). From this preliminary experiment a concentration of 10´4 M SNAP was
judged to be the most appropriate for the subsequent experiments.
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Figure 6. NO concentration at extracellular and intracellular level in EA.hy926 cells treated with 
SNAP. EA.hy926 cells were treated with SNAP 10−6–10−3 M for 2 h. Then, NO was quantified in the 
extracellular medium by Griess test (A) or at intracellular level by the fluorescent dye DAF-2 DA and 
expressed as Relative Fluorescence Units (RFU); (B) Data are the mean ± S.E.M. of five samples per 
group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control. 
The treatment of the EA.hy926 endothelial cells with 10−4 M NAMI-A, RuEDTA and KP1339  
for 2 h significantly counteracted the NO increase induced by the contemporary treatment with  
an equimolar concentration of SNAP in either the extracellular medium and intracellularly  
(Figure 7A,B). At the intracellular level, the NO scavenging ability of the ruthenium compounds was 
comparable, and even more pronounced than that of the standard NO scavenger PTIO. The increase 
of NO release in the extracellular medium upon PTIO treatment (Figure 7A) was the consequence of 
its mechanism of action, as already reported above. The NO scavenging ability of the ruthenium 
compounds during the contemporary exposure to the NO donor SNAP was further investigated to 
verify the relationship between the effect and the concentration tested (Figure 8A,B); NAMI-A and 
RuEDTA showed a concentration-dependent reduction of NO at either the extracellular and 
intracellular levels. 
Figure 6. NO concentration at extracellular and intracellular level in EA.hy926 cells treated with
SNAP. EA.hy926 cells were treated with SNAP 10´6–10´3 M for 2 h. Then, NO was quantified in the
extracellular medium by Griess test (A) or at intracellular level by the fluorescent dye DAF-2 DA and
expressed as Relative Fluorescence Units (RFU); (B) Data are the mean ˘ S.E.M. of five samples per
group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control.
The treatment of the EA.hy926 endothelial cells with 10´4 M NAMI-A, RuEDTA and KP1339
for 2 h significantly counteracted the NO increase induced by the contemporary treatment with an
equimolar concentration of SNAP in either the extracellular medium and intracellularly (Figure 7A,B).
At the intracellular level, the NO scavenging ability of the ruthenium compounds was comparable,
and even more pronounced than that of the standard NO scavenger PTIO. The increase of NO release
in the extracellular medium upon PTIO treatment (Figure 7A) was the con equence of its mechanism
of action, as already reported above. The NO scav nging abil ty of the ruthenium compounds during
the contemporary exposure to the NO donor SNAP was further investigat d to v rify the relationship
between the effect and the concentration tested (Figure 8A,B); NAMI-A and RuEDTA showed a
concentration-dependent reduction of NO at either the extracellular and intracellular levels.
Int. J. Mol. Sci. 2016, 17, 1254 7 of 17
Int. J. Mol. Sci. 2016, 17, 1254 7 of 17 
 
(A) 
PTIO NAMI-A Ru-EDTA KP1339
-100
-50
0
50
100
150
N
O
 re
le
as
e
%
 o
f v
ar
ia
tio
n 
vs
 S
N
A
P
***
***
***
***°°°^^^
°°°
 
(B) PTIO NAMI-A Ru-EDTA KP1339
-100
-80
-60
-40
-20
0
In
tr
ac
el
lu
la
r N
O
%
 o
f v
ar
ia
tio
n 
vs
 S
N
A
P 
***
*** ******  
Figure 7. Effects of the contemporary treatment with NAMI-A, Ru-EDTA, KP1339, and PTIO on 
SNAP induced NO production/release by EA.hy926 cells. EA.hy926 cells were treated with 10−4 M 
SNAP ± an equimolar concentration of compounds for 2 h. Then, NO was measured in the 
extracellular medium by Griess test (A) or at intracellular level by the fluorescent dye DAF-2 DA;  
(B) Data are expressed as per cent of variation vs. SNAP treated cells and are the mean ± S.E.M. of 
five samples per group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control, °°° p < 0.001 vs. 
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Figure 7. Effects of the contemporary treatment with NAMI-A, Ru-EDTA, KP1339, and PTIO on
SNAP induced NO production/release by EA.hy926 cells. EA.hy926 cells were treated with 10´4 M
SNAP˘ an equimolar concentration of compounds for 2 h. Then, NO was measured in the extracellular
medium by Griess test (A) or at intracellular level by the fluorescent dye DAF-2 DA; (B) Data are
expressed as per cent of variation vs. SNAP treated cells and are the mean ˘ S.E.M. of five samples per
group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control, ˝˝˝ p < 0.001 vs. KP1339; ˆˆˆ p < 0.001
vs. Ru-EDTA.
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Figure 8. Concentration-dependent effects of the contemporary treatment with NAMI-A, Ru-EDTA, 
and PTIO on SNAP induced NO production/release by EA.hy926 cells. EA.hy926 cells were treated 
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in the extracellular medium by Griess test (A) or at intracellular level by the fluorescent dye DAF-2 
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of five samples per group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control. 
The treatment with NAMI-A, RuEDTA, and KP1339, as well as with the positive control PTIO, 
for 2 h before the cell exposure to the NO donor SNAP, maintained their ability to reduce the NO 
levels inside the cells (Figure 9B). The effect was similar for the three ruthenium compounds, 
although quantitatively attenuated, in comparison to that observed with the contemporary 
treatment (approximately −25% vs. −90%; compare Figures 9B and 7B). As expected, the 
pre-treatment with the ruthenium compounds, as well with PTIO, was completely ineffective to 
modulate the NO levels in the extra-cellular medium (Figure 9A). 
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Figure 9. Effects of the pre-treatment with NAMI-A, Ru-EDTA, KP1339, and PTIO on SNAP induced 
NO production/release by EA.hy926 cells. EA.hy926 cells were pre-treated with 10−4 M NAMI-A, 
Ru-EDTA, KP1339, and PTIO for 2 h, then, after washing, with an equimolar concentration of SNAP 
for further 2 h. NO was measured in the extracellular medium by Griess test (A) or at intracellular level 
by the fluorescent dye DAF-2 DA; (B) Data are expressed as per cent of variation vs. SNAP treated cells 
and are the mean ± S.E.M. of five samples per group. ANOVA and Tukey–Kramer: ** p < 0.01 vs. Control. 
Figure 8. Concentration-dependent effects of the contemporary treatment with NAMI-A, Ru-EDTA,
and PTIO on SNAP induced NO production/release by EA.hy926 cells. EA.hy926 cells were treated
with 3 ˆ 10´4 M SNAP ˘ 10´5 and 10´4 M concentration of compounds for 2 h. Then, NO was
measured in the extracellular medium by Griess test (A) or at intracellular level by the fluorescent
dye DAF-2 DA; (B) Data are expressed as per cent of variation vs. SNAP treated cells and are the
mean ˘ S.E.M. of five samples per group. ANOVA and Tukey–Kramer: *** p < 0.001 vs. Control.
The treatment with NAMI-A, RuEDTA, and KP1339, as well as with the positive control PTIO,
for 2 h before the cell exposure to the NO donor SNAP, maintained their ability to reduce the
NO levels inside the cells (Figure 9B). The effect was similar for the three ruthenium compounds,
although quantitatively attenuated, in comparison to that observed with the contemporary treatment
(approximately ´25% vs. ´90%; compare Figures 9B and 7B). As expected, the pre-treatment with the
ruthenium compounds, as well with PTIO, was completely ineffective to modulate the NO levels in
the extra-cellular medium (Figure 9A).
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NO production/release by EA.hy926 cells. EA.hy926 cells were pre-treated with 10−4 M NAMI- , 
Ru-EDTA, KP1339, and PTIO for 2 h, then, after washing, with an equimolar concentration of SNAP 
for f rther 2 h. NO was measured in the extracellular medium by Griess test (A) or at intracellular level 
by the fluorescent dye DAF-2 DA; (B) Data are expressed as per cent of variation vs. SNAP treated cells 
and are the mean ± S.E.M. of five samples per group. ANOVA and Tukey–Kramer: ** p < 0.01 vs. Control. 
Figure 9. Effects of the pre-treatment with NAMI-A, Ru-EDTA, KP1339, and PTIO on SNAP induced
NO production/release by EA.hy926 cells. EA.hy926 cells were pre-treated with 10´4 M NAMI-A,
Ru-EDTA, KP1339, and PTIO for 2 h, then, after washing, with an equimolar conce tration of SNAP for
further 2 h. NO was measured in the extracellular medium by Griess tes (A) or at in rac llular level
by the fluorescent dye DAF-2 DA; (B) Data are expressed as per cent of variation vs. SNAP treated
cells and are the mean ˘ S.E.M. of five samples per group. ANOVA and Tukey–Kramer: ** p < 0.01
vs. Control.
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The NO scavenging ability of NAMI-A and RuEDTA at the intracellular level was measurable
and it was relevant also when the treatment with the NO donor SNAP preceded the cell exposure
to the ruthenium compounds (Figure 10). Once again the activity of the ruthenium compounds
was quantitatively comparable (approximately ´45% independently of the compound being tested).
As expected, the detection of NO in the extracellular medium of control cells was under the threshold
level (data not shown).
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Figure 10. Effects of the post-treatment with NAMI-A, Ru-EDTA, and PTIO on SNAP induced NO 
production/release by EA.hy926 cells. EA.hy926 cells were pre-treated with 10−4 M SNAP for 2 h and 
then, after washing, with NAMI-A, Ru-EDTA, and PTIO for further 2 h. Then, NO was measured at 
intracellular level by the fluorescent dye DAF-2 DA. Data are expressed as per cent of variation vs. 
SNAP treated cells and are the mean ± S.E.M. of five samples per group. ANOVA and 
Tukey–Kramer: * p < 0.05, ** p < 0.01 vs. Control. 
2.3. Anti-Angiogenic Activity of NAMI-A in the Model of Matrigel™ Pellets 
The morphological analysis of control Matrigel™ pellets showed a remarkable angiogenic 
activity, characterized by a diffuse network of blood vessels and an overt red colour (Figure 11A, left). 
In contrast, the pellets containing NAMI-A presented a pale coloration, indicative of a lesser 
presence of vessels (Figure 11A, right). This observation was confirmed by the quantitative analysis  
of the haemoglobin content in the pellets that was remarkably lower (−90%) in the treated group  
(Figure 11B). 
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production/release by EA.hy926 cells. EA.hy926 cells were pre-treated with 10´4 M SNAP for 2 h and
then, after ashing, ith A I-A, Ru-EDTA, and PTIO for further 2 h. Then, O as easured at
intracellular level by the fluorescent dye DAF-2 DA. Data are expressed as per cent of variation vs.
S P treated cells and are the mean ˘ S.E.M. of five samples per group. ANOVA and Tukey–Kramer:
* p < 0.05, ** p < 0.01 vs. Control.
2.3. Anti-Angiogenic Activity of NAMI-A in the Model of Matrigel™ Pellets
The morphological analysis of control Matrigel™ pellets showed a remarkable angiogenic activity,
characterized by a diffuse network of blood vessels and an overt red colour (Figure 11A, left).
In contrast, the pellets containing NAMI-A presented a pale coloration, indicative of a lesser presence
of vessels (Figure 11A, right). This observation was confirmed by the quantitative analysis of the
haemoglobin content in the pellets that was remarkably lower (´90%) in the treated group (Figure 11B).
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Figure 11. Anti-angiogenic activity of NAMI-A in the model of Matrigel™ pellets. The Matrigel™ 
pellets containing vascular endothelial growth factor (VEGF), heparin, TNF-α and phosphate 
buffered saline (PBS) (controls), or 2 × 10−4 M NAMI-A (treated) were implanted subcutaneously 
(s.c.) in C57/BL 6N mice. After four days, the pellets were explanted, photographed (A) and the 
haemoglobin content measured with the method of Drabkin; (B) Data are the mean ± S.E.M. of three 
samples. Unpaired t-test: *** p < 0.001 vs. Controls. 
3. Discussion 
A significant impulse to the study and development of anticancer complexes of ruthenium has 
been given by the pioneering works with the so-called “symmetrical bis-heterocycles 
ruthenium(III)” [18] and with the dimethylsulphoxide-containing ruthenium(II) and later 
ruthenium(III) compounds [19,20]. If the initial idea was to mimic cisplatin in either potency or 
mechanism of action, suddenly the “ruthenium-sulphoxides” showed a low level of cell cytotoxicity 
in vitro [21] and a relatively modest activity against the primary sites of growth of syngenic mouse 
tumours in vivo [22]. On the contrary, these metal-based compounds exhibited an innovative 
capacity to control the development of secondary tumours (metastases) with either mouse models of 
solid tumours [23,24] and leukaemias [25]. The progress of knowledge on the contribution of 
angiogenesis to the development of tumour metastases prompted us to verify whether the 
anti-metastatic properties of NAMI-A (the most studied ruthenium-based complex on mouse 
models of tumour metastases [22–27]) could be ascribed to the control of the angiogenic process. 
These studies showed NAMI-A capable of inhibiting angiogenesis in all the test systems employed, 
namely the CAM model [8], the rabbit cornea model [9] and the Matrigel™ sponges implanted 
subcutaneously in the mouse of the present study. 
NO is a key factor that stimulates the migration of endothelial cells during the angiogenesis 
process [13,28] and the interaction of ruthenium complexes with the nitrosyl ligand has been widely 
investigated [29–31]. All the ruthenium complexes tested in the present study have proven to control 
the production and release of NO by cells involved in the angiogenic processes facilitating the 
growth of tumours such as the macrophages and the endothelial cells (these latter here represented 
by the immortalized EA.hy926 cell line). It could be speculatively said that the anti-angiogenic 
activity of the complexes of the present study is due to their capacity to bind this small gaseous 
molecule as already demonstrated with the infrared spectroscopy [9]. In the case of the ruthenium 
complex NAMI-A, support to the role of NO scavenging for its innovative anti-tumour properties is 
given by the study of Das and Mondal [32] who have stressed the capacity of the adduct of NAMI-A 
with serum albumin to efficiently bind the nitrosyls, then immediately to undergo reduction to the 
more reactive ruthenium(II), a phenomenon that in the mind of these authors would explain the 
anti-metastatic properties of this drug. However, if the scavenging of extracellular NO can be easily 
understood, it is questionable that the reduction of the intracellular NO may depend on the same 
mechanism, given the demonstrated NAMI-A inability to penetrate into the cells [33]. 
Although capable of scavenging NO similarly to NAMI-A, RuEDTA and KP1339 do not share 
the same ability of NAMI-A to inhibit the endothelial cell invasion, suggesting that mechanisms 
others than NO scavenging are likely responsible of this activity, such as the reduced 
Figure 11. Anti-angiogenic activity of NAMI-A in the model of Matrigel™ pellets. The Matrigel™
pellets containing vascular endothelial growth factor (VEGF), heparin, TNF-α and phosphate buffered
saline (PBS) (controls), or 2 ˆ 10´4 M NAMI-A (treated) were implanted subcutaneously (s.c.) in
C57/BL 6N mice. After four days, the pellets were explanted, photographed (A) and the haemoglobin
content measured with the method of Drabkin; (B) Data are the mean ˘ S.E.M. of three samples.
Unpaired t-test: *** p < 0.001 vs. Controls.
3. Discussion
A significant impulse to the study and development of anticancer complexes of ruthenium
has been given by the pioneering works with the so-called “symmetrical bis-heterocycles
ruthenium(III)” [18] and with the dimethylsulphoxide-containing ruthenium(II) and later
ruthenium(III) compounds [19,20]. If the initial idea was to mimic cisplatin in either potency or
mechanism of action, suddenly the “ruthenium-sulphoxides” showed a low level of cell cytotoxicity
in vitro [21] and a relatively modest activity against the primary sites of growth of syngenic mouse
tumours in vivo [22]. On the contrary, these metal-based compounds exhibited an innovative capacity
to control the development of secondary tumours (metastases) with either mouse models of solid
tumours [23,24] and leukaemias [25]. The progress of knowledge on the contribution of angiogenesis to
the development of tumour metastases prompted us to verify whether the anti-metastatic properties of
NAMI-A (the most studied ruthenium-based complex on mouse models of tumour metastases [22–27])
could be ascribed to the control of the angiogenic process. These studies showed NAMI-A capable of
inhibiting angiogenesis in all the test systems employed, namely the CAM model [8], the rabbit cornea
model [9] and the Matrigel™ sponges implanted subcutaneously in the mouse of the present study.
NO is a key factor that stimulates the migration of endothelial cells during the angiogenesis
process [13,28] and the interaction of ruthenium complexes with the nitrosyl ligand has been widely
investigated [29–31]. All the ruthenium complexes tested in the present study have proven to control
the production and release of NO by cells involved in the angiogenic processes facilitating the growth
of tumours such as the macrophages and the endothelial cells (these latter here represented by the
immortalized EA.hy926 cell line). It could be speculatively said that the anti-angiogenic activity of the
complexes of the present study is due to their capacity to bind this small gaseous molecule as already
demonstrated with the infrared spectroscopy [9]. In the case of the ruthenium complex NAMI-A,
support to the role of NO scavenging for its innovative anti-tumour properties is given by the study of
Das and Mondal [32] who have stressed the capacity of the adduct of NAMI-A with serum albumin to
efficiently bind the nitrosyls, then immediately to undergo reduction to the more reactive ruthenium(II),
a phenomenon that in the mind of these authors would explain the anti-metastatic properties of this
drug. However, if the scavenging of extracellular NO can be easily understood, it is questionable that
the reduction of the intracellular NO may depend on the same mechanism, given the demonstrated
NAMI-A inability to penetrate into the cells [33].
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Although capable of scavenging NO similarly to NAMI-A, RuEDTA and KP1339 do not share the
same ability of NAMI-A to inhibit the endothelial cell invasion, suggesting that mechanisms others
than NO scavenging are likely responsible of this activity, such as the reduced production/activation of
MMPs caused by NAMI-A but not by the other ruthenium compounds ([8]; Callerio Foundation Onlus,
data on file) It descends that the control of the production/release of NO is not sufficient to claim
for anti-angiogenic properties for a given compound that correspondingly cannot be charged with
capacities of controlling all the tumour cell activities related to angiogenesis. The anti-angiogenic effects
of NAMI-A, here surrogated by the in vitro reduced invasive ability of EA.hy926 endothelial cells, are
confirmed by the in vivo Matrigel™ pellets experiment, and further supported by a parallel study with
aorta rings cultivated in vitro and exposed to increasing concentrations of the ruthenium-based drug.
The results of this study can be summarized as follows: rat aorta rings obtained from healthy adult
Wistar male rats, cultivated in vitro at 37 ˝C in Petri dishes over a Matrigel™ layer, allow the endothelial
cells to grow forming elongated chains of cells invading the Matrigel™ structure. The addition of
NAMI-A significantly reduces endothelial cell outgrowth from aorta rings in a dose-dependent manner
and up to a complete suppression of the phenomenon at 3 ˆ 10´4 M. The model was checked with
SNAP (positive control that induces a pronounced increase of endothelial cell growth around the aorta
ring) and with L-NAME (significant inhibition of the growth of endothelial cells around the aorta
rings) (Callerio Foundation Onlus, data on file). This result confirms what already reported on the
anti-angiogenic activity of NAMI-A adding a further model of angiogenesis in which the phenomenon
is perturbed by concentrations of NAMI-A attainable with those obtained in vivo in the organs where
tumour metastases are formed and grow [12].
The use and the results obtained with the reference standards PTIO, L-NAME and SNAP confirm
the adequacy of the experimental protocols used to test the activity of NAMI-A and of the two other
ruthenium complexes on the modulation of NO production. As expected, L-NAME reduces and
SNAP increases the eNOS expression in the tested cells, as resulting from a series of Western blot
analyses (Callerio Foundation Onlus, data on file). Therefore, the effects of NAMI-A and RuEDTA
(marked reduction of eNOS expression) have pharmacological consistency. Similarly, the effect of
L-NAME on the aorta rings cultivated in vitro (inhibition of the growth of endothelial structures), and
those of SNAP (consistent promotion of endothelial growth), strengthen the meaning of the activity
observed with NAMI-A on the same model and they provide for this drug evidence of the link between
inhibition of eNOS, reduction of NO levels and inhibition of the angiogenesis.
In conclusion, even examining the angiogenesis, NAMI-A proves to have unique qualities not
shared with other ruthenium complexes, and is also very similar to the compound KP1339. The
anti-angiogenic properties of NAMI-A are attributable in part to its capacity to remove the extracellular
NO, even when the drug is bound to serum albumin (the greater amount of the drug in the blood
after intravenous injection [34]), and in part to its ability to modify the activity of transcription factors
responsible for the production of NO, as shown in cells cultured in vitro for 1 h in the presence of
anti-metastatic concentrations of the drug [35]. Although these data are not meant to attribute the
anti-metastatic properties of NAMI-A solely to one’s ability to exert anti-angiogenic activity, they
unequivocally show the strong capacity of this drug to counteract the tumour cell angiogenesis. It is
less clear why this property contributes to the reduction of tumour metastases, while it apparently
does not apply on the primary site of growth of solid tumours, on which the angiogenesis is similarly
important, and on which the effects of NAMI-A have always been quite moderate if not completely
null. If it is not excluded that the anti-angiogenic effect of NAMI-A may contribute to the inhibition
of the release of metastatic cells from the primary tumour, it is almost surprising that the reduction
of angiogenesis at this level does not induce also suffering of tumour cells at this site. Clarifying this
aspect will increase the knowledge on the pharmacological properties of NAMI-A and will give a
further impulse to the development of this class of innovative metal-based drugs.
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4. Materials and Methods
4.1. Compounds and Chemicals
NAMI-A, imidazolium trans-imidazoledimethylsulfoxidetetrachlororuthenate(III), ImH
[trans-RuCl4(DMSO)(Im)], was prepared according to the published procedure [36]. RuEDTA,
potassiumchlorido(ethylendiamminotetraacetate)rutenate(III), K[Ru(HEDTA)Cl], was prepared
according to the published procedure [37] and kindly provided by the group of Luigi Messori,
University of Florence (Florence, Italy). KP1339, sodium (bis-indazole)tetrachloro-ruthenate(III),
Na[trans-RuCl4Ind2], was kindly provided by Bernhard Keppler, University of Vienna
(Vienna, Austria).
2-Phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO), S-nitroso-N-acetyl-DL-penicillamine
(SNAP), Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME) and all other reagents were
purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise indicated.
The structures of the three ruthenium compounds, PTIO, SNAP, and L-NAME, are shown in
Scheme 1.
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Scheme 1. Schematic representation of the chemical structure of
trans-i idazoledi ethylsulphoxidetetrachloro-ruthenate (NAMI-A), sodium (bis-indazole)tetrachloro-
ruthenate(III), Na[trans-RuCl4Ind2] (KP1339), potassiumchlorido(ethylendiamminotetraacetate)
rutenate(III) (RuEDTA), and of 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO),
S-nitroso-N-acetyl-DL-penicillamine (SNAP), and Nω-nitro-L-arginine methyl ester hydrochloride
(L- ME).
4.2. Murine Peritoneal Macrophages
Murine peritoneal macrophages were obtained according to the procedure described by
Zhang et al. [38]. To this purpose, adult male Centro di Biotecnologie Avanzate (CBA) mice from
an established colony of the animal house of the University of Trieste were used. Animal studies
were carried out according to the guidelines in force in Italy (DDL 116 of 21/2/1992 and subsequent
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addenda) and in compliance with the Guide for the Care and Use of Laboratory Animals, DHHS pub.
No. (NIH) 86–23, Bethesda, MD: NIH, 1985. Briefly, donor mice were injected in the peritoneal cavity
with 1 mL of a 3% thioglycollate solution in sterile water. After four days, mice were euthanized with
CO2, the abdomen of each mouse soaked with 70% alcohol and a small incision carried out along the
midline with sterile scissors, then the abdominal skin was retracted to expose the intact peritoneal wall.
Five millilitres of cold PBS (Phosphate Buffered Saline pH = 7.4) were injected into the peritoneum
of each mouse, and then the fluid was aspirated from the peritoneum and dispensed into a 50 mL
centrifuge tube on ice. The peritoneal exudate cells were centrifuged at 400ˆ g for 5 min at 4 ˝C, and
the supernatant discarded and the cell pellet re-suspended in Roswell Park Memorial Insitute culture
medium 1640 (RPMI) medium containing 0.25 M Hepes (EuroClone, Devon, UK) and 105 cells/well
seeded into a 96-well plate. After 2 h, the supernatant was discarded, cells were washed twice with
PBS and macrophages maintained in RPMI culture medium supplemented with 10% foetal bovine
serum (FBS, Invitrogen, Paisley, Scotland, UK), 2 mM L-glutamine (EuroClone), 100 IU/mL Penicillin,
100 µg/mL streptomycin (EuroClone), 0.5% gentamicin, 4 ˆ 10´4 M sodium pyruvate (EuroClone),
0.25 M Hepes (EuroClone), and 1% non-essential amino acids (EuroClone).
4.3. EA.hy926 Cell Line
The human endothelial-like immortalised cell line EA.hy926, derived from the fusion of human
umbelical vein endothelial cells (HUVEC) with the lung carcinoma cell line A549 was kindly provided
by Mauro Coluccia, University of Bari, Bari, Italy, and was maintained in Dulbecco’s modified Eagle’s
medium (DMEM, EuroClone), supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine,
100 IU/mL penicillin and 100 µg/mL streptomycin.
The cell line was kept in an incubator with 5% CO2 and 100% relative humidity at 37 ˝C. Cells
from a confluent monolayer were removed from flasks by a trypsin-EDTA solution. Cell viability was
determined by the trypan blue dye exclusion test. For experimental purposes, cells were sown in flasks
or in multi-well culture clusters.
4.4. Cytotoxicity Test
Cells were seeded at 5000 per well on 96-well plates and allowed to grow until they reached
a sub-confluence stage. Then, they were incubated for 48 and 72 h with 10´6–10´3 M solutions of
NAMI-A, RuEDTA, KP1339, PTIO, SNAP, and L-NAME obtained by serial dilution of a stock solution
(freshly prepared in sterile water at a concentration of 2 mM) with complete medium containing
5% FBS. Analysis of cell cytotoxicity by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay was performed after 48 or 72 h of incubation. Briefly, MTT dissolved in PBS (5 mg/mL)
was added (10 µL per 100 µL medium) to all wells, and the plates were then incubated at 37 ˝C with
5% CO2 and 100% relative humidity for 4 h. After this time, the medium was discarded and 200 µL of
a 10% Igepal® solution in HCl 0.01 N were added to each well for 30 min at 37 ˝C. Absorbance units
were measured at λ = 570 nm on an Automated Microplate Reader EL311s (BIO-TEK® Instruments,
Winooski, VT, USA). IC50 values were calculated from dose–effect curves and are the mean ˘ standard
deviation (S.D.) of at least three separate experiments. The fitting procedure applied is a nonlinear
regression performed with GraphPad Prism version 6 for Mac OS X version 6.0b (GraphPad Software,
San Diego, CA, USA). Experiments were conducted in quadruplicate and repeated three times.
4.5. Invasion Assay
Invasion assay was performed using 8.0 µm pore size Transwell® inserts (Costar, Cambridge, MA,
USA) coated with Matrigel™ (400 µg/mL, BD, Milano, Italy) at room temperature overnight. EA.hy926
cells were treated with NAMI-A, RuEDTA, SNAP, and L-NAME (10´5, 10´4, and 3 ˆ 10´4 M) in
serum-starved medium for 24 h at 37 ˝C, 5% CO2 before being seeded on inserts (105 cells/insert) in
the same medium containing 0.1% bovine serum albumine (BSA). As invasion stimulus, the complete
medium was applied in the plate wells, as negative control to detect the basal invasion rate a serum-free
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medium was used. After 24 h, cells that had remained on the upper side of the membrane were
removed using cotton swabs, while the cells that invaded and were present in the lower surface of
the inserts were fixed with methanol, stained with May-Grünwald-Giemsa and observed at light
microscopy (400ˆ) (Orthoplan, Leitz, Wetzlar, Germany). Cells that have invaded have been counted
in 7 fields. The results are expressed as percentage of treated/untreated cells.
4.6. Nitric Oxide Measurements
Murine peritoneal macrophages were seeded at 105/well into 96-well plates in complete medium
and treated with the compounds and with 10 µg/mL LPS (Lipopolysaccharide), accordingly to
literature data reporting that, in the presence of LPS, the production of nitric oxide was found to
be induced in macrophages in a time- and dose-dependent manner [16]. The NO production was
measured by the Griess test.
EA.hy926 cells were seeded at 5000/well into 96-well plates in complete medium and treated
with the compounds. The quantification of NO in the extracellular medium was measured by the
Griess test while the fluorescent probe DAF-2 DA (Molecular Probes, Eugene, OR, USA) was used to
detect NO at intracellular level.
4.7. Griess Test
Nitric oxide (NO) was determined on supernatants of cell cultures with Griess reagent according
to Stuher and Nathan [39]. Briefly, supernatants of cultures (85 µL) were put in microtitre 96-well
plates and added with 5 µL nitrate reductase and 10 µL NADH for 20 min at room temperature (RT),
and then with 100 µL Griess reagent (1% naphtylethylendiamine to 1% sulphanilamide, 1:1). After
10 min at RT, the absorbance units were measured at 540 nm. NaNO2 was used as standard.
4.8. DAF-2 DA Fluorescent Probe
Diamminofluoresceins are usually used to detect NO in the intracellular milieu. DAF-2 DA has
been widely applied to study NO in endothelial cells [40,41]. It enters by diffusion into cells where it is
hydrolysed by cytosol esterases releasing the DAF-2 specie, which in the presence of NO and O2 is
converted to the fluorescent derivative DAF-2T. The probe was added to the growth medium at 5 µM
for 45 min at 37 ˝C and 5% CO2. The fluorescence (excitation at 492 nm and emission at 515 nm) was
measured by a fluorimeter FluoroCount™ (Packard, Milano, Italy).
4.9. Matrigel™ Pellets Angiogenic Test
The experiment was carried out at the Centro di Biotecnologie Avanzate (CBA) of the University
of Genua, in collaboration with the group of Adriana Albini. C57/BL 6 N male mice were implanted
subcutaneously (s.c.) with 600 µL of Matrigel™ added with VEGF (36 ng/pellet), heparin (12 U/pellet),
TNF-α (0.72 ng/pellet) and PBS (for the controls) or NAMI-A to obtain a final concentration of
2.4 ˆ 10´4 M. Four days after the implant mice were sacrificed with CO2, and the pellets extracted,
photographed and processed for the determination of the haemoglobin content. Briefly, the pellets
were put in eppendorf tubes with water and disaggregated mechanically with the aid of scissors.
After centrifugation the supernatant was collected and the haemoglobin content determined with a
kit purchased from Sigma and based on the method of Drabkin [42]. The procedure is a colorimetric
cyanomethaemoglobin method where total haemoglobin at alkaline pH is rapidly converted to the
cyanoderivative. The absorbance of the cyanoderivative is determined at 540 nm. The haemoglobin
content was then normalized to the weight of the pellets.
4.10. Statistical Analysis
Results obtained were processed using InstatGraph3 software (Version 3.0, GraphPad Software
Inc., San diego, CA, USA) and presented as mean ˘ mean ˘ standard error medium (S.E.M.) The group
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means were compared using a Two-Way Analysis of Variance (ANOVA) followed by Tukey–Kramer
post-test and considered significant when p < 0.05.
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